IP Review

Unattributed Code Systems

• http://example.com/codelists/CL_ntprobnp_unit
• http://example.org
• http://loinc.org
• http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
• http://snomed.info/sct
• http://unitsofmeasure.org
• http://unstats.un.org/unsd/methods/m49/m49.htm
• http://www.nlm.nih.gov/research/umls/rxnorm
• http://www.whocc.no/atc
• https://fevir.net/sevco
• https://www.cas.org/support/documentation/chemical-substances
• https://www.meddra.org
• https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
• https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn
• https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
• https://www.nlm.nih.gov/mesh
• urn:ietf:bcp:47
• urn:iso:std:iso:3166
• urn:oid:2.16.840.1.113883.6.238

Copyright Fragment

This fragment is available on en/index.html

Error parsing IP fragment: unable to parse character reference ' Conditions in https://www.whocc.no/use_of_atc_ddd/'' (last text = ' ' at line 14 column 272

Copyright and Registered Trademark Uses

• IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-snapshot1. Generated 2026-11-05 Links: Table of Contents | QA Report | Version History | CC0 | Propose a change ( src )
• ®© HL7 | Creative Commons 0 ( src )
• Evidence Based Medicine on FHIR Implementation Guide ®© HL7 | Creative Commons 0 ( src )
• 15.883 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• : SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267223. Revised 2026-09-24. Available at: https://fevir.net/resources/ResearchStudy/267223. Computable resource at: https://fevir.net/resources/ResearchStudy/267223#json. ( src )
• Adverse Events Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399874. Revised 2026-09-24. Available at: https://fevir.net/resources/Composition/399874. Computable resource at: https://fevir.net/resources/Composition/399874#json. ( src )
• Adverse Events Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370505. Revised 2026-09-24. Available at: https://fevir.net/resources/Composition/370505. Computable resource at: https://fevir.net/resources/Composition/370505#json. ( src )
• Analysis of formalin-fixed paraffin-embedded and blood and blood samples (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583783. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583783. Computable resource at: https://fevir.net/resources/EvidenceVariable/583783#json. ( src )
• Artifact Author: Computable Publishing®: CTIS-to-FEvIR Converter: ( src )
• Artifact Author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: ( src )
• Assess emergent resistant mutations (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583782. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583782. Computable resource at: https://fevir.net/resources/EvidenceVariable/583782#json. ( src )
• Baseline Characteristics Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399872. Revised 2026-09-24. Available at: https://fevir.net/resources/Composition/399872. Computable resource at: https://fevir.net/resources/Composition/399872#json. ( src )
• Baseline Characteristics Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370503. Revised 2026-09-24. Available at: https://fevir.net/resources/Composition/370503. Computable resource at: https://fevir.net/resources/Composition/370503#json. ( src )
• Change in Mean Diastolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367884. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367884. Computable resource at: https://fevir.net/resources/EvidenceVariable/367884#json. ( src )
• Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367943. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367943. Computable resource at: https://fevir.net/resources/Evidence/367943#json. ( src )
• Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367908. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367908. Computable resource at: https://fevir.net/resources/Evidence/367908#json. ( src )
• Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367907. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367907. Computable resource at: https://fevir.net/resources/Evidence/367907#json. ( src )
• Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367882. Revised 2026-09-24. Available at: https://fevir.net/resources/EvidenceVariable/367882. Computable resource at: https://fevir.net/resources/EvidenceVariable/367882#json. ( src )
• Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367941. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367941. Computable resource at: https://fevir.net/resources/Evidence/367941#json. ( src )
• Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367904. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367904. Computable resource at: https://fevir.net/resources/Evidence/367904#json. ( src )
• Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367903. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367903. Computable resource at: https://fevir.net/resources/Evidence/367903#json. ( src )
• Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367891. Revised 2026-09-24. Available at: https://fevir.net/resources/EvidenceVariable/367891. Computable resource at: https://fevir.net/resources/EvidenceVariable/367891#json. ( src )
• Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367951. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367951. Computable resource at: https://fevir.net/resources/Evidence/367951#json. ( src )
• Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367926. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367926. Computable resource at: https://fevir.net/resources/Evidence/367926#json. ( src )
• Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367925. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367925. Computable resource at: https://fevir.net/resources/Evidence/367925#json. ( src )
• Clinical benefit rate (CBR) (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583772. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583772. Computable resource at: https://fevir.net/resources/EvidenceVariable/583772#json. ( src )
• Codes for use with the Classifier drop-down menu for FEvIR(R): Recommendation Justification Builder. ( src )
• Computable Publishing® augments digital publishing with machine-interpretable forms. Computable Publishing® offers publishers of any type (commercial, nonprofit, academic, government) the ability to extend their published works with computable (machine-interpretable) forms of expression, and users of any type support in using computable data to enhance, improve and achieve desired outcomes. ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Executable app], version 4.9.1. Contributors: Computable Publishing LLC [Author]. In: Fast Evidence Interoperability Resources (FEvIR) Platform. Published June 04, 2021. Revised October 09, 2023. Accessed November 25, 2023. Available at: https://fevir.net/ctgovconvert. ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter converts ClinicalTrials.gov JSON to FEvIR Resources in FHIR® JSON. • Enter an NCT Identifier (NCTID) and click Submit. • FHIR Resources will be created for all Protocol and Results Section Data in the ClinicalTrials.gov record. • For related articles listed in MEDLINE, the Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter automates use of the Computable Publishing®: MEDLINE-to-FEvIR Converter. ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter is one of the many Converter tools on the FEvIR Platform. • Converter Tools transform data between known structured forms and the FHIR standard form. • The FEvIR Platform provides access to an array of tools which enable creating and viewing scientific knowledge in standard-based, machine-interpretable units called Resources. ( src )
• Copyright © 2011 Elsevier Ltd. All rights reserved. ( src )
• Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved. ( src )
• Copyright © 2013 Elsevier Inc. All rights reserved. ( src )
• Copyright © 2013 Elsevier Ltd. All rights reserved. ( src )
• Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved. ( src )
• Copyright © 2015 Elsevier Inc. All rights reserved. ( src )
• Copyright © 2015 Elsevier Ltd. All rights reserved. ( src )
• Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. ( src )
• Copyright © 2021 Massachusetts Medical Society. All rights reserved. ( src )
• Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ( src )
• Copyright/Legal: Portions of this material derives from the ICH M11 Harmonised Guideline CeSHarP. The ICH M11 Harmonised Guideline CeSHarP is copyright ©2025+ International Committee on Harmonisation and is made available under license. CDISC publishes semantics for the ICH M11 protocol data elements and valid value sets. This terminology set is published and stored in the NCI Thesaurus Subset C217023 - ICH M11 Terminology (https://evsexplore.semantics.cancer.gov/evsexplore/subset/ncit/C217023) The NCI Thesaurus is released under the CC BY 4.0 license Further details at https://hl7.org/fhir/uv/clinical-study-protocol/2026May/en/ValueSet-m11-amendment-details-statement-vs.html ( src )
• Copyright/Legal: Portions of this material derives from the ICH M11 Harmonised Guideline CeSHarP. The ICH M11 Harmonised Guideline CeSHarP is copyright ©2025+ International Committee on Harmonisation and is made available under license. CDISC publishes semantics for the ICH M11 protocol data elements and valid value sets. This terminology set is published and stored in the NCI Thesaurus Subset C217023 - ICH M11 Terminology (https://evsexplore.semantics.cancer.gov/evsexplore/subset/ncit/C217023) The NCI Thesaurus is released under the CC BY 4.0 license Further details at https://hl7.org/fhir/uv/clinical-study-protocol/2026May/en/ValueSet-m11-amendment-reason-vs.html ( src )
• Copyright/Legal: Portions of this material derives from the ICH M11 Harmonised Guideline CeSHarP. The ICH M11 Harmonised Guideline CeSHarP is copyright ©2025+ International Committee on Harmonisation and is made available under license. CDISC publishes semantics for the ICH M11 protocol data elements and valid value sets. This terminology set is published and stored in the NCI Thesaurus Subset C217023 - ICH M11 Terminology (https://evsexplore.semantics.cancer.gov/evsexplore/subset/ncit/C217023) The NCI Thesaurus is released under the CC BY 4.0 license Further details at https://hl7.org/fhir/uv/clinical-study-protocol/2026May/en/ValueSet-m11-amendment-scope-enrollment-vs.html ( src )
• Copyright/Legal: Portions of this material derives from the ICH M11 Harmonised Guideline CeSHarP. The ICH M11 Harmonised Guideline CeSHarP is copyright ©2025+ International Committee on Harmonisation and is made available under license. CDISC publishes semantics for the ICH M11 protocol data elements and valid value sets. This terminology set is published and stored in the NCI Thesaurus Subset C217023 - ICH M11 Terminology (https://evsexplore.semantics.cancer.gov/evsexplore/subset/ncit/C217023) The NCI Thesaurus is released under the CC BY 4.0 license Further details at https://hl7.org/fhir/uv/clinical-study-protocol/2026May/en/ValueSet-m11-amendment-scope-vs.html ( src )
• Copyright/Legal: Portions of this material derives from the ICH M11 Harmonised Guideline CeSHarP. The ICH M11 Harmonised Guideline CeSHarP is copyright ©2025+ International Committee on Harmonisation and is made available under license. CDISC publishes semantics for the ICH M11 protocol data elements and valid value sets. This terminology set is published and stored in the NCI Thesaurus Subset C217023 - ICH M11 Terminology (https://evsexplore.semantics.cancer.gov/evsexplore/subset/ncit/C217023) The NCI Thesaurus is released under the CC BY 4.0 license Further details at https://hl7.org/fhir/uv/clinical-study-protocol/2026May/en/ValueSet-m11-phase-vs.html ( src )
• Copyright/Legal: Portions of this material derives from the ICH M11 Harmonised Guideline CeSHarP. The ICH M11 Harmonised Guideline CeSHarP is copyright ©2025+ International Committee on Harmonisation and is made available under license. CDISC publishes semantics for the ICH M11 protocol data elements and valid value sets. This terminology set is published and stored in the NCI Thesaurus Subset C217023 - ICH M11 Terminology (https://evsexplore.semantics.cancer.gov/evsexplore/subset/ncit/C217023) The NCI Thesaurus is released under the CC BY 4.0 license Further details at https://hl7.org/fhir/uv/clinical-study-protocol/2026May/en/ValueSet-m11-yes-no-vs.html ( src )
• Copyright/Legal: Portions of this material derives from the ICH M11 Harmonised Guideline CeSHarP. The ICH M11 Harmonised Guideline CeSHarP is copyright ©2025+ International Committee on Harmonisation and is made available under license. CDISC publishes semantics for the ICH M11 protocol data elements and valid value sets. This terminology set is published and stored in the NCI Thesaurus Subset C217023 - ICH M11 Terminology (https://evsexplore.semantics.cancer.gov/evsexplore/subset/ncit/C217023) The NCI Thesaurus is released under the CC BY 4.0 license Further details at https://hl7.org/fhir/uv/clinical-study-protocol/2026May/en/ValueSet-udp-identifier-type-vs.html ( src )
• Copyright/Legal: Portions of this material derives from the ICH M11 Harmonised Guideline CeSHarP. The ICH M11 Harmonised Guideline CeSHarP is copyright ©2025+ International Committee on Harmonisation and is made available under license. CDISC publishes semantics for the ICH M11 protocol data elements and valid value sets. This terminology set is published and stored in the NCI Thesaurus Subset C217023 - ICH M11 Terminology (https://evsexplore.semantics.cancer.gov/evsexplore/subset/ncit/C217023) The NCI Thesaurus is released under the CC BY 4.0 license Further details at https://hl7.org/fhir/uv/clinical-study-protocol/2026May/en/ValueSet-udp-party-role-type-vs.html ( src )
• Copyright/Legal: Portions of this material derives from the ICH M11 Harmonised Guideline CeSHarP. The ICH M11 Harmonised Guideline CeSHarP is copyright ©2025+ International Committee on Harmonisation and is made available under license. CDISC publishes semantics for the ICH M11 protocol data elements and valid value sets. This terminology set is published and stored in the NCI Thesaurus Subset C217023 - ICH M11 Terminology (https://evsexplore.semantics.cancer.gov/evsexplore/subset/ncit/C217023) The NCI Thesaurus is released under the CC BY 4.0 license. ( src )
• Correlate baseline mutations with treatment response (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583780. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583780. Computable resource at: https://fevir.net/resources/EvidenceVariable/583780#json. ( src )
• Correlate changes in ctDNA variant allele frequencies with response (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583781. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583781. Computable resource at: https://fevir.net/resources/EvidenceVariable/583781#json. ( src )
• Correlate mutation profiles with tumor sequencing (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583779. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583779. Computable resource at: https://fevir.net/resources/EvidenceVariable/583779#json. ( src )
• Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583777. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583777. Computable resource at: https://fevir.net/resources/EvidenceVariable/583777#json. ( src )
• Defines the content expected to be rendered in all representations of the artifact. The (c) symbol should NOT be included in this string. It is expected to be added by software when rendering the notation. Full details about licensing, restrictions, warrantees, etc. goes in the more general 'copyright' element. ( src )
• Duration of response (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583771. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583771. Computable resource at: https://fevir.net/resources/EvidenceVariable/583771#json. ( src )
• Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: CTIS-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 346485. Revised 2026-08-13. Available at: https://fevir.net/resources/ResearchStudy/346485. Computable resource at: https://fevir.net/resources/ResearchStudy/346485#json. ( src )
• Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367879. Revised 2026-10-06. Available at: https://fevir.net/resources/ResearchStudy/367879. Computable resource at: https://fevir.net/resources/ResearchStudy/367879#json. ( src )
• Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions ( src )
• Example PublicationRecord: SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• GLUCAGEN® and GLUCAGEN® Hypokit 1 mg (glucagon) Product Monograph. Mississauga, Ontario: Novo Nordisk Canada Inc.; 2014. http://www.paladin-labs.com/our_products/PM_GlucaGen_EN.pdf. Accessed 26 September 2015. ( src )
• Gene expression profiling (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583778. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583778. Computable resource at: https://fevir.net/resources/EvidenceVariable/583778#json. ( src )
• GroupAssignment: GLP-1 RA vs. Standard care [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236536. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236536. Computable resource at: https://fevir.net/resources/EvidenceVariable/236536#json. ( src )
• GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236950. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236950. Computable resource at: https://fevir.net/resources/EvidenceVariable/236950#json. ( src )
• Health-related Quality of Life (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367890. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367890. Computable resource at: https://fevir.net/resources/EvidenceVariable/367890#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370509. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/370509. Computable resource at: https://fevir.net/resources/EvidenceVariable/370509#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367924. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367924. Computable resource at: https://fevir.net/resources/Evidence/367924#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367923. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367923. Computable resource at: https://fevir.net/resources/Evidence/367923#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370508. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/370508. Computable resource at: https://fevir.net/resources/EvidenceVariable/370508#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367922. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367922. Computable resource at: https://fevir.net/resources/Evidence/367922#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367921. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367921. Computable resource at: https://fevir.net/resources/Evidence/367921#json. ( src )
• Incidence of adverse events (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583775. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583775. Computable resource at: https://fevir.net/resources/EvidenceVariable/583775#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557345. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557345. Computable resource at: https://fevir.net/resources/Evidence/557345#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557021. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557021. Computable resource at: https://fevir.net/resources/Evidence/557021#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557376. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557376. Computable resource at: https://fevir.net/resources/Evidence/557376#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557046. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557046. Computable resource at: https://fevir.net/resources/Evidence/557046#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557348. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557348. Computable resource at: https://fevir.net/resources/Evidence/557348#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557024. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557024. Computable resource at: https://fevir.net/resources/Evidence/557024#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557363. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557363. Computable resource at: https://fevir.net/resources/Evidence/557363#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557357. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557357. Computable resource at: https://fevir.net/resources/Evidence/557357#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557033. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557033. Computable resource at: https://fevir.net/resources/Evidence/557033#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557369. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557369. Computable resource at: https://fevir.net/resources/Evidence/557369#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557374. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557374. Computable resource at: https://fevir.net/resources/Evidence/557374#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557044. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557044. Computable resource at: https://fevir.net/resources/Evidence/557044#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557360. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557360. Computable resource at: https://fevir.net/resources/Evidence/557360#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557036. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557036. Computable resource at: https://fevir.net/resources/Evidence/557036#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557351. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557351. Computable resource at: https://fevir.net/resources/Evidence/557351#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557027. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557027. Computable resource at: https://fevir.net/resources/Evidence/557027#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557354. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557354. Computable resource at: https://fevir.net/resources/Evidence/557354#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557030. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557030. Computable resource at: https://fevir.net/resources/Evidence/557030#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557366. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557366. Computable resource at: https://fevir.net/resources/Evidence/557366#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557039. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557039. Computable resource at: https://fevir.net/resources/Evidence/557039#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557372. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557372. Computable resource at: https://fevir.net/resources/Evidence/557372#json. ( src )
• MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557042. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557042. Computable resource at: https://fevir.net/resources/Evidence/557042#json. ( src )
• MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557019. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557019. Computable resource at: https://fevir.net/resources/Evidence/557019#json. ( src )
• MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557343. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557343. Computable resource at: https://fevir.net/resources/Evidence/557343#json. ( src )
• MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236567. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/236567. Computable resource at: https://fevir.net/resources/Evidence/236567#json. ( src )
• MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236987. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/236987. Computable resource at: https://fevir.net/resources/Evidence/236987#json. ( src )
• MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557022. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557022. Computable resource at: https://fevir.net/resources/Evidence/557022#json. ( src )
• MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557346. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557346. Computable resource at: https://fevir.net/resources/Evidence/557346#json. ( src )
• MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557361. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557361. Computable resource at: https://fevir.net/resources/Evidence/557361#json. ( src )
• MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557031. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557031. Computable resource at: https://fevir.net/resources/Evidence/557031#json. ( src )
• MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557355. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557355. Computable resource at: https://fevir.net/resources/Evidence/557355#json. ( src )
• MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557367. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557367. Computable resource at: https://fevir.net/resources/Evidence/557367#json. ( src )
• MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236564. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/236564. Computable resource at: https://fevir.net/resources/Evidence/236564#json. ( src )
• MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236984. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/236984. Computable resource at: https://fevir.net/resources/Evidence/236984#json. ( src )
• MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557034. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557034. Computable resource at: https://fevir.net/resources/Evidence/557034#json. ( src )
• MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557358. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557358. Computable resource at: https://fevir.net/resources/Evidence/557358#json. ( src )
• MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557025. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557025. Computable resource at: https://fevir.net/resources/Evidence/557025#json. ( src )
• MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557349. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557349. Computable resource at: https://fevir.net/resources/Evidence/557349#json. ( src )
• MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557028. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557028. Computable resource at: https://fevir.net/resources/Evidence/557028#json. ( src )
• MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557352. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557352. Computable resource at: https://fevir.net/resources/Evidence/557352#json. ( src )
• MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557037. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557037. Computable resource at: https://fevir.net/resources/Evidence/557037#json. ( src )
• MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557364. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557364. Computable resource at: https://fevir.net/resources/Evidence/557364#json. ( src )
• MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557040. Revised 2026-08-29. Available at: https://fevir.net/resources/Evidence/557040. Computable resource at: https://fevir.net/resources/Evidence/557040#json. ( src )
• MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557370. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557370. Computable resource at: https://fevir.net/resources/Evidence/557370#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557020. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557020. Computable resource at: https://fevir.net/resources/Evidence/557020#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557344. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557344. Computable resource at: https://fevir.net/resources/Evidence/557344#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557045. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557045. Computable resource at: https://fevir.net/resources/Evidence/557045#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557375. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557375. Computable resource at: https://fevir.net/resources/Evidence/557375#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557023. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557023. Computable resource at: https://fevir.net/resources/Evidence/557023#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557347. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557347. Computable resource at: https://fevir.net/resources/Evidence/557347#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557362. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557362. Computable resource at: https://fevir.net/resources/Evidence/557362#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557032. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557032. Computable resource at: https://fevir.net/resources/Evidence/557032#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557356. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557356. Computable resource at: https://fevir.net/resources/Evidence/557356#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557368. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557368. Computable resource at: https://fevir.net/resources/Evidence/557368#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557043. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557043. Computable resource at: https://fevir.net/resources/Evidence/557043#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557373. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557373. Computable resource at: https://fevir.net/resources/Evidence/557373#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557035. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557035. Computable resource at: https://fevir.net/resources/Evidence/557035#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557359. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557359. Computable resource at: https://fevir.net/resources/Evidence/557359#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557026. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557026. Computable resource at: https://fevir.net/resources/Evidence/557026#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557350. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557350. Computable resource at: https://fevir.net/resources/Evidence/557350#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557029. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557029. Computable resource at: https://fevir.net/resources/Evidence/557029#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557353. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557353. Computable resource at: https://fevir.net/resources/Evidence/557353#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557038. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557038. Computable resource at: https://fevir.net/resources/Evidence/557038#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557365. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557365. Computable resource at: https://fevir.net/resources/Evidence/557365#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557041. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557041. Computable resource at: https://fevir.net/resources/Evidence/557041#json. ( src )
• MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557371. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557371. Computable resource at: https://fevir.net/resources/Evidence/557371#json. ( src )
• Mean Change in Blood Urea Nitrogen (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367901. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367901. Computable resource at: https://fevir.net/resources/EvidenceVariable/367901#json. ( src )
• Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367957. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367957. Computable resource at: https://fevir.net/resources/Evidence/367957#json. ( src )
• Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367938. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367938. Computable resource at: https://fevir.net/resources/Evidence/367938#json. ( src )
• Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367937. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367937. Computable resource at: https://fevir.net/resources/Evidence/367937#json. ( src )
• Mean Change in Serum Creatinine (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367902. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367902. Computable resource at: https://fevir.net/resources/EvidenceVariable/367902#json. ( src )
• Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367958. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367958. Computable resource at: https://fevir.net/resources/Evidence/367958#json. ( src )
• Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367940. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367940. Computable resource at: https://fevir.net/resources/Evidence/367940#json. ( src )
• Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367939. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367939. Computable resource at: https://fevir.net/resources/Evidence/367939#json. ( src )
• Mean Change in Serum Potassium (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367899. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367899. Computable resource at: https://fevir.net/resources/EvidenceVariable/367899#json. ( src )
• Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367955. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367955. Computable resource at: https://fevir.net/resources/Evidence/367955#json. ( src )
• Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367934. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367934. Computable resource at: https://fevir.net/resources/Evidence/367934#json. ( src )
• Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367933. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367933. Computable resource at: https://fevir.net/resources/Evidence/367933#json. ( src )
• Mean Change in Serum Sodium (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367900. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367900. Computable resource at: https://fevir.net/resources/EvidenceVariable/367900#json. ( src )
• Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367956. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367956. Computable resource at: https://fevir.net/resources/Evidence/367956#json. ( src )
• Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367936. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367936. Computable resource at: https://fevir.net/resources/Evidence/367936#json. ( src )
• Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367935. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367935. Computable resource at: https://fevir.net/resources/Evidence/367935#json. ( src )
• Mean Diastolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367885. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367885. Computable resource at: https://fevir.net/resources/EvidenceVariable/367885#json. ( src )
• Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367944. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367944. Computable resource at: https://fevir.net/resources/Evidence/367944#json. ( src )
• Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367910. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367910. Computable resource at: https://fevir.net/resources/Evidence/367910#json. ( src )
• Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367909. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367909. Computable resource at: https://fevir.net/resources/Evidence/367909#json. ( src )
• Mean Systolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367883. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367883. Computable resource at: https://fevir.net/resources/EvidenceVariable/367883#json. ( src )
• Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367942. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367942. Computable resource at: https://fevir.net/resources/Evidence/367942#json. ( src )
• Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367906. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367906. Computable resource at: https://fevir.net/resources/Evidence/367906#json. ( src )
• Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367905. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367905. Computable resource at: https://fevir.net/resources/Evidence/367905#json. ( src )
• Medication Adherence (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367889. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367889. Computable resource at: https://fevir.net/resources/EvidenceVariable/367889#json. ( src )
• Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367948. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367948. Computable resource at: https://fevir.net/resources/Evidence/367948#json. ( src )
• Medication Adherence at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367920. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367920. Computable resource at: https://fevir.net/resources/Evidence/367920#json. ( src )
• Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367919. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367919. Computable resource at: https://fevir.net/resources/Evidence/367919#json. ( src )
• Mental Health T Score at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367950. Revised 2026-09-24. Available at: https://fevir.net/resources/Evidence/367950. Computable resource at: https://fevir.net/resources/Evidence/367950#json. ( src )
• Methods Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia. They were randomly assigned to receive supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care or standard of care medications alone. The primary endpoint was the proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization. This trial was registered with clinicaltrials.gov, NCT04401202. ( src )
• More than 20 uses of ©, ®, (R), (TM) or (C) on en/Composition-399871.html: stopped looking for them there - check the page directly ( src )
• More than 20 uses of ©, ®, (R), (TM) or (C) on en/Composition-399871.json.html: stopped looking for them there - check the page directly ( src )
• More than 20 uses of ©, ®, (R), (TM) or (C) on en/Composition-399871.ttl.html: stopped looking for them there - check the page directly ( src )
• More than 20 uses of ©, ®, (R), (TM) or (C) on en/Composition-399871.xml.html: stopped looking for them there - check the page directly ( src )
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. ( src )
• Number of Patients Requiring Step up Treatment (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367887. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367887. Computable resource at: https://fevir.net/resources/EvidenceVariable/367887#json. ( src )
• Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367946. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367946. Computable resource at: https://fevir.net/resources/Evidence/367946#json. ( src )
• Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367916. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367916. Computable resource at: https://fevir.net/resources/Evidence/367916#json. ( src )
• Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367915. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367915. Computable resource at: https://fevir.net/resources/Evidence/367915#json. ( src )
• Objective response rate (ORR) (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583770. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583770. Computable resource at: https://fevir.net/resources/EvidenceVariable/583770#json. ( src )
• Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2026-09-24. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json. ( src )
• Outcome Measures Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370504. Revised 2026-09-24. Available at: https://fevir.net/resources/Composition/370504. Computable resource at: https://fevir.net/resources/Composition/370504#json. ( src )
• OutcomeDefinition for All-cause mortality [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236953. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236953. Computable resource at: https://fevir.net/resources/EvidenceVariable/236953#json. ( src )
• OutcomeDefinition for Body weight [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236986. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236986. Computable resource at: https://fevir.net/resources/EvidenceVariable/236986#json. ( src )
• OutcomeDefinition for Cardiovascular mortality [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236956. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236956. Computable resource at: https://fevir.net/resources/EvidenceVariable/236956#json. ( src )
• OutcomeDefinition for End-stage kidney disease [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236965. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236965. Computable resource at: https://fevir.net/resources/EvidenceVariable/236965#json. ( src )
• OutcomeDefinition for Health-related quality of life [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236983. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236983. Computable resource at: https://fevir.net/resources/EvidenceVariable/236983#json. ( src )
• OutcomeDefinition for Heart failure [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236968. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236968. Computable resource at: https://fevir.net/resources/EvidenceVariable/236968#json. ( src )
• OutcomeDefinition for Nonfatal myocardial infarction [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236959. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236959. Computable resource at: https://fevir.net/resources/EvidenceVariable/236959#json. ( src )
• OutcomeDefinition for Nonfatal stroke [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236962. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236962. Computable resource at: https://fevir.net/resources/EvidenceVariable/236962#json. ( src )
• OutcomeDefinition for Serious hyperglycaemia [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236974. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236974. Computable resource at: https://fevir.net/resources/EvidenceVariable/236974#json. ( src )
• OutcomeDefinition for Severe gastrointestinal events [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236980. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236980. Computable resource at: https://fevir.net/resources/EvidenceVariable/236980#json. ( src )
• OutcomeDefinition: All-cause mortality [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236539. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236539. Computable resource at: https://fevir.net/resources/EvidenceVariable/236539#json. ( src )
• OutcomeDefinition: Body weight [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236566. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236566. Computable resource at: https://fevir.net/resources/EvidenceVariable/236566#json. ( src )
• OutcomeDefinition: Cardiovascular mortality [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236542. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236542. Computable resource at: https://fevir.net/resources/EvidenceVariable/236542#json. ( src )
• OutcomeDefinition: Diabetic ketoacidosis [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236971. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236971. Computable resource at: https://fevir.net/resources/EvidenceVariable/236971#json. ( src )
• OutcomeDefinition: End-stage kidney disease [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236551. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236551. Computable resource at: https://fevir.net/resources/EvidenceVariable/236551#json. ( src )
• OutcomeDefinition: Genital infection [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236977. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236977. Computable resource at: https://fevir.net/resources/EvidenceVariable/236977#json. ( src )
• OutcomeDefinition: Health-related quality of life [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236563. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236563. Computable resource at: https://fevir.net/resources/EvidenceVariable/236563#json. ( src )
• OutcomeDefinition: Heart failure [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236554. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236554. Computable resource at: https://fevir.net/resources/EvidenceVariable/236554#json. ( src )
• OutcomeDefinition: Nonfatal myocardial infarction [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236545. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236545. Computable resource at: https://fevir.net/resources/EvidenceVariable/236545#json. ( src )
• OutcomeDefinition: Nonfatal stroke [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236548. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236548. Computable resource at: https://fevir.net/resources/EvidenceVariable/236548#json. ( src )
• OutcomeDefinition: Serious hyperglycaemia [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236557. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236557. Computable resource at: https://fevir.net/resources/EvidenceVariable/236557#json. ( src )
• OutcomeDefinition: Severe gastrointestinal events [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236560. Revised 2026-08-06. Available at: https://fevir.net/resources/EvidenceVariable/236560. Computable resource at: https://fevir.net/resources/EvidenceVariable/236560#json. ( src )
• Overall survival (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583774. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583774. Computable resource at: https://fevir.net/resources/EvidenceVariable/583774#json. ( src )
• PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267228. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267228. Computable resource at: https://fevir.net/resources/EvidenceVariable/267228#json. ( src )
• PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267237. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267237. Computable resource at: https://fevir.net/resources/Evidence/267237#json. ( src )
• PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267236. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267236. Computable resource at: https://fevir.net/resources/Evidence/267236#json. ( src )
• PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267230. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267230. Computable resource at: https://fevir.net/resources/EvidenceVariable/267230#json. ( src )
• PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267241. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267241. Computable resource at: https://fevir.net/resources/Evidence/267241#json. ( src )
• PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267240. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267240. Computable resource at: https://fevir.net/resources/Evidence/267240#json. ( src )
• PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267231. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267231. Computable resource at: https://fevir.net/resources/EvidenceVariable/267231#json. ( src )
• PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267243. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267243. Computable resource at: https://fevir.net/resources/Evidence/267243#json. ( src )
• PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267242. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267242. Computable resource at: https://fevir.net/resources/Evidence/267242#json. ( src )
• Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2026-09-24. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json. ( src )
• Participant Flow Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370502. Revised 2026-09-24. Available at: https://fevir.net/resources/Composition/370502. Computable resource at: https://fevir.net/resources/Composition/370502#json. ( src )
• Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267226. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267226. Computable resource at: https://fevir.net/resources/EvidenceVariable/267226#json. ( src )
• Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267244. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267244. Computable resource at: https://fevir.net/resources/Evidence/267244#json. ( src )
• Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267233. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267233. Computable resource at: https://fevir.net/resources/Evidence/267233#json. ( src )
• Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267232. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267232. Computable resource at: https://fevir.net/resources/Evidence/267232#json. ( src )
• Percentage of Participants With Clinical Recovery Within 14 Days After Randomization (NCT04401202) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 5269. Revised 2026-08-05. Available at: https://fevir.net/resources/EvidenceVariable/5269. Computable resource at: https://fevir.net/resources/EvidenceVariable/5269#json. ( src )
• Percentage of Participants With Potentially Related Adverse Events (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367897. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367897. Computable resource at: https://fevir.net/resources/EvidenceVariable/367897#json. ( src )
• Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367953. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367953. Computable resource at: https://fevir.net/resources/Evidence/367953#json. ( src )
• Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367930. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367930. Computable resource at: https://fevir.net/resources/Evidence/367930#json. ( src )
• Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367929. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367929. Computable resource at: https://fevir.net/resources/Evidence/367929#json. ( src )
• Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367896. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367896. Computable resource at: https://fevir.net/resources/EvidenceVariable/367896#json. ( src )
• Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367952. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367952. Computable resource at: https://fevir.net/resources/Evidence/367952#json. ( src )
• Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367928. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367928. Computable resource at: https://fevir.net/resources/Evidence/367928#json. ( src )
• Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367927. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367927. Computable resource at: https://fevir.net/resources/Evidence/367927#json. ( src )
• Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267227. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267227. Computable resource at: https://fevir.net/resources/EvidenceVariable/267227#json. ( src )
• Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267235. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267235. Computable resource at: https://fevir.net/resources/Evidence/267235#json. ( src )
• Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267234. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267234. Computable resource at: https://fevir.net/resources/Evidence/267234#json. ( src )
• Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267229. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267229. Computable resource at: https://fevir.net/resources/EvidenceVariable/267229#json. ( src )
• Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267239. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267239. Computable resource at: https://fevir.net/resources/Evidence/267239#json. ( src )
• Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267238. Revised 2026-09-02. Available at: https://fevir.net/resources/Evidence/267238. Computable resource at: https://fevir.net/resources/Evidence/267238#json. ( src )
• Physical Health T Score at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367949. Revised 2026-09-24. Available at: https://fevir.net/resources/Evidence/367949. Computable resource at: https://fevir.net/resources/Evidence/367949#json. ( src )
• Progression-free survival (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583773. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583773. Computable resource at: https://fevir.net/resources/EvidenceVariable/583773#json. ( src )
• Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367888. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367888. Computable resource at: https://fevir.net/resources/EvidenceVariable/367888#json. ( src )
• Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367947. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367947. Computable resource at: https://fevir.net/resources/Evidence/367947#json. ( src )
• Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367918. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367918. Computable resource at: https://fevir.net/resources/Evidence/367918#json. ( src )
• Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367917. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367917. Computable resource at: https://fevir.net/resources/Evidence/367917#json. ( src )
• Proportion of Patients With Hypertension Control (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367886. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367886. Computable resource at: https://fevir.net/resources/EvidenceVariable/367886#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370507. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/370507. Computable resource at: https://fevir.net/resources/EvidenceVariable/370507#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367914. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367914. Computable resource at: https://fevir.net/resources/Evidence/367914#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367913. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367913. Computable resource at: https://fevir.net/resources/Evidence/367913#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370506. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/370506. Computable resource at: https://fevir.net/resources/EvidenceVariable/370506#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367912. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367912. Computable resource at: https://fevir.net/resources/Evidence/367912#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367911. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367911. Computable resource at: https://fevir.net/resources/Evidence/367911#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367945. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367945. Computable resource at: https://fevir.net/resources/Evidence/367945#json. ( src )
• Rate of Adverse Events of Special Interest (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367898. Revised 2026-09-08. Available at: https://fevir.net/resources/EvidenceVariable/367898. Computable resource at: https://fevir.net/resources/EvidenceVariable/367898#json. ( src )
• Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367954. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367954. Computable resource at: https://fevir.net/resources/Evidence/367954#json. ( src )
• Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367932. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367932. Computable resource at: https://fevir.net/resources/Evidence/367932#json. ( src )
• Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367931. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367931. Computable resource at: https://fevir.net/resources/Evidence/367931#json. ( src )
• Results Section for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267224. Revised 2026-09-02. Available at: https://fevir.net/resources/Composition/267224. Computable resource at: https://fevir.net/resources/Composition/267224#json. ( src )
• Results Section for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367880. Revised 2026-09-08. Available at: https://fevir.net/resources/Composition/367880. Computable resource at: https://fevir.net/resources/Composition/367880#json. ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3 ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - JSON Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3 ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - TTL Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3 ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - XML Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3 ( src )
• Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583768. Revised 2026-08-13. Available at: https://fevir.net/resources/ResearchStudy/583768. Computable resource at: https://fevir.net/resources/ResearchStudy/583768#json. ( src )
• The copyright symbol and the '(c)' textual representation SHOULD NOT be included in this string. It will be added by software when rendering the notation. Full details about licensing, restrictions, warrantees, etc. goes in the more general 'copyright' element. ( src )
• The purpose of this research was to describe and interpret the positive body image experiences of women actively engaged in pole fitness. A total of seven women between the ages of 20 and 36 years participated in semistructured one-on-one interviews and follow-up interviews. Participant observation was also used to generate data. Data were analyzed using an interpretative phenomenological analysis approach, and the positive body image experiences of women are represented by five themes: (a) observation and exposure fostering body acceptance, (b) performance promoting self-confidence, (c) personal growth and sexual expression, (d) unconditional community support creates comfort, and (e) body appreciation through physical skill development. Findings suggest that women engaging in pole fitness may experience positive body image, and the words of participants provide insight into the components of pole fitness that may foster positive body image. Pole fitness may provide a unique exercise context whereby women can develop and maintain positive body image. ( src )
• The short copyright declaration (e.g. (c) '2015+ xyz organization' should be sent in the copyrightLabel element. ( src )
• The short copyright declaration (e.g. (c) '2015+ xyz organization') should be sent in the copyrightLabel element without the copyright prefix (i.e., do not include '(c)' or the symbol). ( src )
• This material contains content from LOINC. LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. Show Usage * LOINC: ARMYDA_Eligibility_Criteria, ComparativeBaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group... Show 81 more, Composition/372776, Composition/568043, Composition/568044, Composition/568045, Composition/568046, Composition/568047, Composition/568048, Composition/568049, Composition/568050, Composition/568051, Composition/568052, Composition/568053, Composition/568054, Composition/568055, Composition/568056, Composition/568057, Composition/568058, Composition/568059, Composition/568060, Composition/568061, Composition/568062, Composition/568063, Composition/568064, Composition/568065, Composition/568066, Composition/568067, Composition/568068, Composition/568069, Composition/568070, Composition/568071, Composition/568072, ConceptualCohortDefinition_At_least_2_risk_factors_for_stroke, ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity, ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, ConceptualCohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, ConceptualCohortDefinition_Oxygen_saturation_below_96_on_Boots_Finger_Pulse_Oximeter, ConceptualCohortDefinition_Oxygen_saturation_below_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges, ConceptualCohortDefinition_Proxy_criteria_for_surgical_candidates, ConceptualCohortDefinition_Severe_obesity, Diastolic_blood_pressure_at_12_weeks, EGFR_45_59, Ethnic_Group, Example_Variable_Definition_for_EBMonFHIR_IG, ExposureVariable_Body_Mass_Index_as_continuous_variable, Group/267506, Group/279346, Group/279347, Group/282882, Group/297750, Hypertension_Control_at_12_weeks, M11ReportContainer, M11ReportSection01, M11ReportSection02, M11ReportSection03, M11ReportSection04, M11ReportSection05, M11ReportSection06, M11ReportSection07, M11ReportSection08, M11ReportSection09, M11ReportSection10, M11ReportSection11, M11ReportSection12, M11ReportSection13, M11ReportSection14, OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control, OutcomeDefinition_HbA1c_at_12_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_6_months, QUARTET_Eligibility_Criteria, StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, StudyEligibilityCriteria_Obese_patients_18_years_old, Systolic_blood_pressure_at_12_weeks and Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis ( src )
• This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html Show Usage * StatisticAttribute Estimate Type: ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014... Show 36 more, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, Example_of_statistical_model_expression, MeanDiffA1c2016metaAnalysis, NCT03421379_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_0_OutcomeAnalysis_11_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_1_OutcomeAnalysis_12_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_2_OutcomeAnalysis_13_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_3_OutcomeAnalysis_14_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_4_OutcomeAnalysis_15_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_5_OutcomeAnalysis_16_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_6_OutcomeAnalysis_17_BetweenGroupAnalysis_OG000_OG001, NCT03640312_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_0_OutcomeAnalysis_1_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_1_OutcomeAnalysis_2_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_2_OutcomeAnalysis_3_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_3_OutcomeAnalysis_4_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_4_OutcomeAnalysis_5_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_5_OutcomeAnalysis_6_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_6_OutcomeAnalysis_7_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_8_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_9_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_8_OutcomeAnalysis_10_BetweenGroupAnalysis_OG000_OG001 and OSFPreprint_PrimaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001 * StatisticCertaintyRating: ArtifactAssessment/179693, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study... Show 8 more, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, EvidenceAssessment, Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY and RiskOfBias * EvidenceDirectness: Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19 and Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY * LibraryType: Library/179606, Library/179618... Show 4 more, Library/179632, SearchResults, SystematicReviewExcludedStudies and SystematicReviewIncludedStudies * List Empty Reasons: Composition/178426, Composition/179465... Show 9 more, Composition/179466, Composition/179467, Composition/179699, Composition/236537, Composition/236538, Composition/236951, Composition/292951, Composition/372776 and Composition/570077 * Organization type: Computable_Publishing_LLC * PlanDefinitionType: ADA_Obesity_Management_Recommendation_8_16, PlanDefinition/179554 and RecommendationPlan * ResearchStudyObjectiveType: CTIS_2024_516402_32_00_FHIR_Transform, NCT03421379_FHIR_Transform... Show 6 more, NCT03421379_FHIR_Transform_M11_IGBJ, NCT03640312_FHIR_Transform, NCT05327010_FHIR_Transform, NMA_Diabetes, ResearchStudy/568025 and ResearchStudy/588219 * Research Study Party Role: CTIS_2024_516402_32_00_FHIR_Transform, NCT03421379_FHIR_Transform... Show 8 more, NCT03421379_FHIR_Transform_M11_IGBJ, NCT03640312_FHIR_Transform, NCT05327010_FHIR_Transform, NMA_Diabetes, ResearchStudy/586129, ResearchStudy/588219, ResearchStudy/588222 and Year_2018_Norwegian_Cohort_Study * ResearchStudyPhase: NCT05327010_FHIR_Transform and ResearchStudy/588219 * Research Study Purpose Type: NCT03421379_FHIR_Transform, NCT03421379_FHIR_Transform_M11_IGBJ... Show 5 more, NCT03640312_FHIR_Transform, NCT05327010_FHIR_Transform, NMA_Diabetes, ResearchStudy/588219 and ResearchStudy/588222 * Research Study Status: CTIS_2024_516402_32_00_FHIR_Transform, NCT03421379_FHIR_Transform... Show 5 more, NCT03421379_FHIR_Transform_M11_IGBJ, NCT03640312_FHIR_Transform, NCT05327010_FHIR_Transform, ResearchStudy/586129 and Year_2018_Norwegian_Cohort_Study * StatisticStatisticType: ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, CIBIC_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version... Show 16 more, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014 and MeanDiffA1c2016metaAnalysis * StatisticSynthesisType: AllCauseMortality2022metaAnalysis, ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study... Show 34 more, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, ComparatorOnlyEvidence_Additional_GI_surgical_procedure_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Myocardial_infarction_or_stroke_without_bariatric_surgery_Control_Group_in_Swedish_Obese_Subjects_SOS_study, ComparatorOnlyEvidence_New_onset_depression_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Remission_of_diabetes_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Treatment_with_opioids_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, Death_or_Major_Traumatic_Injury_on_Impact_comparing_intervention_vs_comparator, Example_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, InterventionOnlyEvidence_Additional_GI_surgical_procedure_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_New_onset_depression_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Remission_of_diabetes_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Treatment_with_opioids_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, MeanDiffA1c2016metaAnalysis, NMA_Diabetes and SingleStudyEvidence * UsageContextType: Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, Group/588218... Show 8 more, PICOClassification, PICOSpecification, PublicationRecord/111, PublicationRecord/112, PublicationRecord/5192, PublicationRecord/5296, PublicationRecord/7636 and PublicationRecord/7638 * identifierType: ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, ADA_Obesity_Management_Recommendation_8_16... Show 757 more, ARMYDA_Eligibility_Criteria, ActivityDefinition/375159, ActivityDefinition/375181, Add_on_Amlodipine_at_6_weeks, Adults_with_type_2_diabetes, Adults_with_type_2_diabetes_with_moderate_CV_risk, Adverse_event_free_and_hypertension_control_at_12_weeks, Age, Age_with_comparator, Age_with_intervention, Aircraft_Type_with_comparator, Aircraft_Type_with_intervention, AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis, All_cause_mortality313876, All_cause_mortality313956, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313876, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313956, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313876, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313956, All_cause_mortality_from_MAGICapp_313876, All_cause_mortality_from_MAGICapp_313956, Altitude, Altitude_comparing_intervention_vs_comparator, Altitude_for_enrolled_group, Altitude_for_screened_group, Altitude_with_comparator, Altitude_with_intervention, An_example_of_OutcomeDefinition_Profile_which_is_a_conceptual_group_used_to_provided_a_definition_for_an_EvidenceVariable, Analysis_of_formalin_fixed_paraffin_embedded_and_blood_and_blood_samples_NCT05327010, ArtifactAssessment/104064, ArtifactAssessment/104192, ArtifactAssessment/104193, ArtifactAssessment/104194, ArtifactAssessment/104195, ArtifactAssessment/104196, ArtifactAssessment/171898, ArtifactAssessment/179448, ArtifactAssessment/179469, ArtifactAssessment/179515, ArtifactAssessment/179692, ArtifactAssessment/179693, ArtifactAssessment/179694, ArtifactAssessment/179698, ArtifactAssessment/179700, ArtifactAssessment/181452, ArtifactAssessment/307449, ArtifactAssessment/385882, ArtifactAssessment/423309, ArtifactAssessment/423310, ArtifactAssessment/423312, ArtifactAssessment/423313, ArtifactAssessment/423314, ArtifactAssessment/423315, Assess_emergent_resistant_mutations_NCT05327010, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17, Bariatric_Surgery_RYGB_VSG_LAGB_BPD, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group, Birthdate, Body_weight109570, Body_weight109588, Body_weight_Comparator_Evidence_from_MAGICapp_109570, Body_weight_Comparator_Evidence_from_MAGICapp_109588, Body_weight_Intervention_Evidence_from_MAGICapp_109570, Body_weight_Intervention_Evidence_from_MAGICapp_109588, Body_weight_from_MAGICapp_109570, Body_weight_from_MAGICapp_109588, CIBIC_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, COVID_19PneumoniaHospitalizedAdult, CTIS2024_516402_32_00_Eligibility_Criteria, CTIS2024_516402_32_00_Primary_Outcome_1, CTIS2024_516402_32_00_Secondary_Outcome_1, CTIS2024_516402_32_00_Secondary_Outcome_2, CTIS2024_516402_32_00_Secondary_Outcome_3, CTIS2024_516402_32_00_Secondary_Outcome_4, CTIS2024_516402_32_00_Secondary_Outcome_5, CTIS2024_516402_32_00_Secondary_Outcome_6, CTIS2024_516402_32_00_Secondary_Outcome_7, CTIS2024_516402_32_00_Secondary_Outcome_8, CTIS_2024_516402_32_00_FHIR_Transform, Cardiovascular_mortality313877, Cardiovascular_mortality313957, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_from_MAGICapp_313877, Cardiovascular_mortality_from_MAGICapp_313957, Case_id, Change_in_Mean_Diastolic_Blood_Pressure_NCT03640312, Change_in_Mean_Systolic_Blood_Pressure_at_12_weeks_NCT03640312, Change_in_Mean_Systolic_Blood_Pressure_at_6_weeks_NCT03640312, Clinical_benefit_rate_CBR_NCT05327010, CodeSystemRecommendationJustification, ComparativeBaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeBaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort, ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial, ComparatorDefinition_Obese_patients_18_years_old_without_bariatric_surgery, ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, ComparatorOnlyEvidence_Additional_GI_surgical_procedure_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Myocardial_infarction_or_stroke_without_bariatric_surgery_Control_Group_in_Swedish_Obese_Subjects_SOS_study, ComparatorOnlyEvidence_New_onset_depression_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Remission_of_diabetes_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Treatment_with_opioids_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, Composition/104215, Composition/104383, Composition/178426, Composition/179465, Composition/179466, Composition/179467, Composition/179699, Composition/236537, Composition/236538, Composition/236951, Composition/292951, Composition/307245, Composition/307248, Composition/312172, Composition/312203, Composition/318262, Composition/342828, Composition/343007, Composition/370502, Composition/370503, Composition/370504, Composition/370505, Composition/370510, Composition/370512, Composition/372776, Composition/375280, Composition/397488, Composition/399871, Composition/399872, Composition/399873, Composition/399874, Composition/568043, Composition/568044, Composition/568045, Composition/568046, Composition/568047, Composition/568048, Composition/568049, Composition/568050, Composition/568051, Composition/568052, Composition/568053, Composition/568054, Composition/568055, Composition/568056, Composition/568057, Composition/568058, Composition/568059, Composition/568060, Composition/568061, Composition/568062, Composition/568063, Composition/568064, Composition/568065, Composition/568066, Composition/568067, Composition/568068, Composition/568069, Composition/568070, Composition/568071, Composition/568072, Composition/570077, Computable_Publishing_LLC, ConceptualCohortDefinition_At_least_2_risk_factors_for_stroke, ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity, ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, ConceptualCohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years, ConceptualCohortDefinition_Cardiovascular_event, ConceptualCohortDefinition_Heart_failure_based_on_Phenotypes, ConceptualCohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration, ConceptualCohortDefinition_Nonfatal_myocardial_infarction, ConceptualCohortDefinition_Nonfatal_stroke, ConceptualCohortDefinition_Oxygen_saturation_below_96_on_Boots_Finger_Pulse_Oximeter, ConceptualCohortDefinition_Oxygen_saturation_below_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges, ConceptualCohortDefinition_Proxy_criteria_for_surgical_candidates, ConceptualCohortDefinition_Severe_obesity, ConceptualComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, ConceptualComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis, ConceptualExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin, Condition_code, Correlate_baseline_mutations_with_treatment_response_NCT05327010, Correlate_changes_in_ctDNA_variant_allele_frequencies_with_response_NCT05327010, Correlate_mutation_profiles_with_tumor_sequencing_NCT05327010, Correlation_of_single_nucleotide_variant_SNV_and_copy_number_variant_CNV_profiles_with_treatment_response_NCT05327010, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, Cs_ebm_ig, DIO_Mortality, Death_or_Major_Traumatic_Injury_30_days_after_Impact_comparing_intervention_vs_comparator, Death_or_Major_Traumatic_Injury_30_days_after_Impact_with_comparator, Death_or_Major_Traumatic_Injury_30_days_after_Impact_with_intervention, Death_or_Major_Traumatic_Injury_on_Impact_comparing_intervention_vs_comparator, Declined_randomization_in_PARACHUTE_Study, Deemed_unsuitable_by_investigator_in_PARACHUTE_Trial, DeviceDefinition/179899, Diabetic_ketoacidosis313962, Diabetic_ketoacidosis_Comparator_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_Intervention_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_from_MAGICapp_313962, Diastolic_blood_pressure_at_12_weeks, DichotomousIntendedOutcome_Additional_gastrointestinal_surgical_procedure, DichotomousIntendedOutcome_Death_or_Major_Traumatic_Injury_within_30_days, DichotomousIntendedOutcome_New_onset_depression, DichotomousIntendedOutcome_Nonfatal_myocardial_infarction_or_stroke, DichotomousIntendedOutcome_Remission_of_diabetes, DichotomousIntendedOutcome_Treatment_with_opioids, DocumentReference/367832, DocumentReference/367833, Duration_of_response_NCT05327010, EGFR_45_59, End_stage_kidney_disease313880, End_stage_kidney_disease313960, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_from_MAGICapp_313880, End_stage_kidney_disease_from_MAGICapp_313960, Ethnic_Group, Ethnic_Group_with_comparator, Ethnic_Group_with_intervention, EvidenceReportSectionCode_Value_Set, EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery, EvidenceVariableHandlingExtensionValueSet, Evidence_for_Results_for_Add_on_Amlodipine_at_6_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Add_on_Amlodipine_at_6_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Add_on_Amlodipine_at_6_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Diastolic_blood_pressure_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Diastolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Diastolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Medication_Adherence_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Medication_Adherence_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Medication_Adherence_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Systolic_blood_pressure_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Systolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Systolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Example_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, Example_Variable_Definition_for_EBMonFHIR_IG, Example_of_statistical_model_expression, Example_variable_definition_for_the_EBMonFHIR_IG, Excluded_from_PARACHUTE_Study, ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort, ExposureVariable_Age_as_continuous_variable, ExposureVariable_Body_Mass_Index_as_continuous_variable, Family_History_of_Parachute_Use, Family_History_of_Parachute_Use_with_comparator, Family_History_of_Parachute_Use_with_intervention, Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY, Frequent_Flier, Frequent_Flier_with_comparator, Frequent_Flier_with_intervention, GLU_J, Gender, Gene_expression_profiling_NCT05327010, Genital_infection313964, Genital_infection_Comparator_Evidence_from_MAGICapp_313964, Genital_infection_Intervention_Evidence_from_MAGICapp_313964, Genital_infection_from_MAGICapp_313964, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85390_I_85789, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85394_C_85798, Group/236535, Group/236948, Group/236949, Group/264323, Group/264328, Group/265092, Group/265093, Group/267506, Group/270503, Group/279340, Group/279346, Group/279347, Group/282882, Group/282891, Group/282899, Group/292955, Group/297486, Group/297487, Group/297488, Group/297489, Group/297750, Group/306655, Group/306657, Group/306658, Group/306659, Group/306660, Group/307440, Group/33395, Group/370701, Group/370702, Group/372797, Group/375175, Group/375182, Group/375279, Group/557017, Group/557018, Group/557341, Group/557342, Group/568026, Group/588218, GroupAssignment_Bariatric_Surgery_vs_no_bariatric_surgery, GroupAssignment_ExposureDefinition_Bariatric_Surgery_RYGB_VSG_LAGB_BPD_vs_ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, GroupAssignment_ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort_vs_ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, GroupAssignment_GLP_1_RA_vs_Standard_care, GroupAssignment_Jumping_from_aircraft_with_parachute_vs_Jumping_from_aircraft_with_empty_backpack, GroupAssignment_Non_Participants_vs_Enrolled_Participants, GroupAssignment_Quadpill_vs_Candesartan, GroupAssignment_Roux_en_Y_gastric_bypass_or_Biliopancreatic_Diversion_vs_medical_treatment, GroupAssignment_Roux_en_Y_gastric_bypass_surgery_vs_Lifestyle_intensive_medical_management_intervention_alone, GroupAssignment_Roux_en_Y_gastric_bypass_vs_medical_treatment, GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA, GroupAssignment_high_dose_xanomeline_vs_low_dose_xanomeline_vs_placebo, Health_Survey_Score_Mental_Health_Subscore, Health_Survey_Score_Mental_Health_Subscore_comparing_intervention_vs_comparator, Health_Survey_Score_Mental_Health_Subscore_with_comparator, Health_Survey_Score_Mental_Health_Subscore_with_intervention, Health_Survey_Score_Physical_Health_Subscore, Health_Survey_Score_Physical_Health_Subscore_comparing_intervention_vs_comparator, Health_Survey_Score_Physical_Health_Subscore_with_comparator, Health_Survey_Score_Physical_Health_Subscore_with_intervention, Health_Survey_Score_Total, Health_Survey_Score_Total_comparing_intervention_vs_comparator, Health_Survey_Score_Total_with_comparator, Health_Survey_Score_Total_with_intervention, Health_related_Quality_of_Life_NCT03640312, Health_related_Quality_of_Life_at_12_weeks_Change_in_Mental_Health_T_score_PROMIS_at_NCT03640312, Health_related_Quality_of_Life_at_12_weeks_Change_in_Physical_Health_T_score_PROMIS_at_NCT03640312, Health_related_quality_of_life109569, Health_related_quality_of_life109587, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_from_MAGICapp_109569, Health_related_quality_of_life_from_MAGICapp_109587, Heart_failure313881, Heart_failure313961, Heart_failure_Comparator_Evidence_from_MAGICapp_313881, Heart_failure_Comparator_Evidence_from_MAGICapp_313961, Heart_failure_Intervention_Evidence_from_MAGICapp_313881, Heart_failure_Intervention_Evidence_from_MAGICapp_313961, Heart_failure_from_MAGICapp_313881, Heart_failure_from_MAGICapp_313961, Height_with_comparator, Height_with_intervention, High_Blood_Pressure_Medication_Value_Set, History_of_Acrophobia, History_of_Acrophobia_with_comparator, History_of_Acrophobia_with_intervention, History_of_Broken_Bones, History_of_Broken_Bones_with_comparator, History_of_Broken_Bones_with_intervention, History_of_Parachute_Use, History_of_Parachute_Use_with_comparator, History_of_Parachute_Use_with_intervention, Hypertension_Control_at_12_weeks, ICD10GM_Terminale_Codes, IV_remdesivir_200_mg_then_100_mg_day_for_9_days, Incidence_of_adverse_events_NCT05327010, Injury_Severity_Score_30_days_after_Impact_comparing_intervention_vs_comparator, Injury_Severity_Score_30_days_after_Impact_with_comparator, Injury_Severity_Score_30_days_after_Impact_with_intervention, Injury_Severity_Score_on_Impact_comparing_intervention_vs_comparator, Injury_Severity_Score_on_Impact_with_comparator, Injury_Severity_Score_on_Impact_with_intervention, International_vs_Domestic_Flight, International_vs_Domestic_Flight_with_comparator, International_vs_Domestic_Flight_with_intervention, InterventionOnlyEvidence_Additional_GI_surgical_procedure_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_New_onset_depression_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Remission_of_diabetes_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Treatment_with_opioids_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, Investigator, Investigator_by_treatment_interaction_for_ADAS_Cog11_ANCOVA, LBDGLUSI, LBXGLU, Library/179606, Library/179618, Library/179632, List/179470, List/179579, List/179585, List/179800, List/307202, List/307246, List/307247, List/312201, List/312205, List/375184, Major_adverse_cardiovascular_events_composite_endpoint, MeanDiffA1c2016metaAnalysis, Mean_Change_in_Blood_Urea_Nitrogen_NCT03640312, Mean_Change_in_Serum_Creatinine_NCT03640312, Mean_Change_in_Serum_Potassium_NCT03640312, Mean_Change_in_Serum_Sodium_NCT03640312, Mean_Diastolic_Blood_Pressure_NCT03640312, Mean_Systolic_Blood_Pressure_NCT03640312, Median_Age_SD, Medication_Adherence_NCT03640312, Medication_Adherence_at_12_weeks, MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs, Mortality14Day, NCT03421379_Eligibility_Criteria, NCT03421379_FHIR_Transform, NCT03421379_FHIR_Transform_M11_IGBJ, NCT03421379_Results, NCT03421379_primaryOutcomeMeasure_0_OG000, NCT03421379_primaryOutcomeMeasure_0_OG001, NCT03421379_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03421379_secondaryOutcomeMeasure_0_OG000, NCT03421379_secondaryOutcomeMeasure_0_OG001, NCT03421379_secondaryOutcomeMeasure_1_OG000, NCT03421379_secondaryOutcomeMeasure_1_OG001, NCT03421379_secondaryOutcomeMeasure_2_OG000, NCT03421379_secondaryOutcomeMeasure_2_OG001, NCT03421379_secondaryOutcomeMeasure_3_OG000, NCT03421379_secondaryOutcomeMeasure_3_OG001, NCT03421379_secondaryOutcomeMeasure_4_OG000, NCT03421379_secondaryOutcomeMeasure_4_OG001, NCT03640312_Eligibility_Criteria, NCT03640312_FHIR_Transform, NCT03640312_Results, NCT03640312_otherOutcomeMeasure_0_OG000, NCT03640312_otherOutcomeMeasure_0_OG001, NCT03640312_otherOutcomeMeasure_0_OutcomeAnalysis_11_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_1_OG000, NCT03640312_otherOutcomeMeasure_1_OG001, NCT03640312_otherOutcomeMeasure_1_OutcomeAnalysis_12_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_2_OG000, NCT03640312_otherOutcomeMeasure_2_OG001, NCT03640312_otherOutcomeMeasure_2_OutcomeAnalysis_13_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_3_OG000, NCT03640312_otherOutcomeMeasure_3_OG001, NCT03640312_otherOutcomeMeasure_3_OutcomeAnalysis_14_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_4_OG000, NCT03640312_otherOutcomeMeasure_4_OG001, NCT03640312_otherOutcomeMeasure_4_OutcomeAnalysis_15_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_5_OG000, NCT03640312_otherOutcomeMeasure_5_OG001, NCT03640312_otherOutcomeMeasure_5_OutcomeAnalysis_16_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_6_OG000, NCT03640312_otherOutcomeMeasure_6_OG001, NCT03640312_otherOutcomeMeasure_6_OutcomeAnalysis_17_BetweenGroupAnalysis_OG000_OG001, NCT03640312_primaryOutcomeMeasure_0_OG000, NCT03640312_primaryOutcomeMeasure_0_OG001, NCT03640312_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_0_OG000, NCT03640312_secondaryOutcomeMeasure_0_OG001, NCT03640312_secondaryOutcomeMeasure_0_OutcomeAnalysis_1_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_1_OG000, NCT03640312_secondaryOutcomeMeasure_1_OG001, NCT03640312_secondaryOutcomeMeasure_1_OutcomeAnalysis_2_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_2_OG000, NCT03640312_secondaryOutcomeMeasure_2_OG001, NCT03640312_secondaryOutcomeMeasure_2_OutcomeAnalysis_3_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_3_12_weeks_OG000, NCT03640312_secondaryOutcomeMeasure_3_12_weeks_OG001, NCT03640312_secondaryOutcomeMeasure_3_6_weeks_OG000, NCT03640312_secondaryOutcomeMeasure_3_6_weeks_OG001, NCT03640312_secondaryOutcomeMeasure_3_OutcomeAnalysis_4_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_4_OG000, NCT03640312_secondaryOutcomeMeasure_4_OG001, NCT03640312_secondaryOutcomeMeasure_4_OutcomeAnalysis_5_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_5_OG000, NCT03640312_secondaryOutcomeMeasure_5_OG001, NCT03640312_secondaryOutcomeMeasure_5_OutcomeAnalysis_6_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_6_OG000, NCT03640312_secondaryOutcomeMeasure_6_OG001, NCT03640312_secondaryOutcomeMeasure_6_OutcomeAnalysis_7_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Mental_Health_T_score_OPEN_PROMIS_CLOSE_OG000, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Mental_Health_T_score_OPEN_PROMIS_CLOSE_OG001, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Physical_Health_T_score_OPEN_PROMIS_CLOSE_OG000, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Physical_Health_T_score_OPEN_PROMIS_CLOSE_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_8_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_9_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_8_OG000, NCT03640312_secondaryOutcomeMeasure_8_OG001, NCT03640312_secondaryOutcomeMeasure_8_OutcomeAnalysis_10_BetweenGroupAnalysis_OG000_OG001, NCT04401202_Eligibility_Criteria, NCT04401202_Enrollment_Group, NCT05327010_Eligibility_Criteria, NCT05327010_FHIR_Transform, NMA_Diabetes, NTproBNP, NetEffectContribution_for_ComparativeEvidence_All_cause_mortality_effect_of_bariatric_surgery_in_2022_meta_analysis, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, NetEffectContribution_for_ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022, NetEffectEstimate_for_SummaryOfNetEffect_Bariatric_Surgery_Summary_of_Net_Effect_Contributions_Example_for_GIN_2022, Nonfatal_myocardial_infarction313878, Nonfatal_myocardial_infarction313958, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_from_MAGICapp_313878, Nonfatal_myocardial_infarction_from_MAGICapp_313958, Nonfatal_stroke313879, Nonfatal_stroke313959, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313959, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313959, Nonfatal_stroke_from_MAGICapp_313879, Nonfatal_stroke_from_MAGICapp_313959, Ntprobnp_comparator, Ntprobnp_date, Ntprobnp_time, Ntprobnp_unit, Number_of_Patients_Requiring_Step_up_Treatment_NCT03640312, OSFPreprint_PrimaryOutcomeMeasure_0_OG000, OSFPreprint_PrimaryOutcomeMeasure_0_OG001, OSFPreprint_PrimaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, Objective_response_rate_ORR_NCT05327010, Organ_support_free_days, OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control, OutcomeDefinition_Diabetes_in_remission, OutcomeDefinition_HbA1c_at_12_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_6_months, OutcomeDefinition_New_onset_depression, OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke, OutcomeVariable_Additional_GI_surgical_procedure, OutcomeVariable_All_cause_mortality, OutcomeVariable_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control_at_5_years, OutcomeVariable_HbA1c_at_12_months, OutcomeVariable_HbA1c_at_24_months, OutcomeVariable_HbA1c_at_36_months, OutcomeVariable_HbA1c_at_60_months, OutcomeVariable_HbA1c_at_6_months, OutcomeVariable_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, OutcomeVariable_New_onset_depression, OutcomeVariable_Nonfatal_myocardial_infarction_or_stroke, OutcomeVariable_Remission_of_diabetes, OutcomeVariable_Treatment_with_opioids, Outcome_Death_or_Major_Traumatic_Injury_30_days_after_Impact, Outcome_Death_or_Major_Traumatic_Injury_on_Impact, Outcome_Injury_Severity_Score_30_days_after_Impact, Outcome_Injury_Severity_Score_on_Impact, Overall_survival_NCT05327010, PARACHUTE_Trial_Participants_available_for_randomization, PARACHUTE_Trial_Participants_deemed_unsuitable_by_investigator, PARACHUTE_Trial_Participants_randomized_into_groups, PARACHUTE_Trial_Participants_randomized_into_groups_for_screened_group, PARACHUTE_Trial_Participants_randomized_into_groups_with_comparator, PARACHUTE_Trial_Participants_randomized_into_groups_with_intervention, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up_with_comparator, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up_with_intervention, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up_with_comparator, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up_with_intervention, PARACHUTE_Trial_Participants_that_declined_randomization, PARACHUTE_Trial_Participants_with_no_contact_at_30_days, PARACHUTE_Trial_Participants_with_no_contact_at_30_days_with_comparator, PARACHUTE_Trial_Participants_with_no_contact_at_30_days_with_intervention, PD_Time_to_Maximal_Concentration_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, PK_Change_From_Baseline_in_Maximal_Concentration_Cmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, PK_Change_From_Baseline_in_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, Parachute_vs_Empty_Backpack_in_PARACHUTE_Trial, ParticipantFlowEvidence_2018_Norwegian_Cohort_Excluded_from_Analysis, ParticipantFlowMeasure_Dropout_due_to_stopping_intervention, ParticipantFlowMeasure_Exclusion_from_analysis, ParticipantFlowMeasure_Inclusion_in_analysis, ParticipantFlow_2018_Norwegian_Cohort_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Medical_Group_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Surgical_Group_Included_in_Analysis, Participants_Excluded_from_PARACHUTE_Study, Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill, Patient_id, Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill, Percentage_of_Participants_Achieving_Treatment_Success_During_Controlled_Insulin_Induced_Hypoglycemia_NCT03421379, Percentage_of_Participants_With_Clinical_Recovery_Within_14_Days_After_Randomization_NCT04401202, Percentage_of_Participants_With_Potentially_Related_Adverse_Events_NCT03640312, Percentage_of_Participants_With_Serious_Adverse_Events_SAEs_NCT03640312, Pharmacodynamics_PD_Change_From_Baseline_in_Maximal_Blood_Glucose_BGmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_Intramuscular_IM_NCT03421379, Pharmacokinetics_PK_Change_From_Baseline_in_Area_Under_the_Concentration_Versus_Time_Curve_From_Zero_to_Time_t_AUC_0_tLast_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, Placebo, PlanDefinition/179554, PlanDefinition/181450, Progression_free_survival_NCT05327010, Proportion_of_Patients_With_Adverse_Event_Free_Hypertension_Control_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_at_6_and_12_weeks_12_weeks_at_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_at_6_and_12_weeks_6_weeks_at_NCT03640312, PublicationRecord/104116, PublicationRecord/105, PublicationRecord/111, PublicationRecord/112, PublicationRecord/121719, PublicationRecord/139859, PublicationRecord/139860, PublicationRecord/153881, PublicationRecord/179558, PublicationRecord/179559, PublicationRecord/179560, PublicationRecord/179561, PublicationRecord/179594, PublicationRecord/179595, PublicationRecord/179596, PublicationRecord/179597, PublicationRecord/179598, PublicationRecord/179599, PublicationRecord/179600, PublicationRecord/179601, PublicationRecord/179602, PublicationRecord/179603, PublicationRecord/179604, PublicationRecord/179605, PublicationRecord/179613, PublicationRecord/179615, PublicationRecord/179616, PublicationRecord/179617, PublicationRecord/179621, PublicationRecord/179622, PublicationRecord/179623, PublicationRecord/179624, PublicationRecord/179625, PublicationRecord/179626, PublicationRecord/179627, PublicationRecord/179628, PublicationRecord/179629, PublicationRecord/179630, PublicationRecord/179631, PublicationRecord/179637, PublicationRecord/247416, PublicationRecord/264329, PublicationRecord/267246, PublicationRecord/267247, PublicationRecord/267496, PublicationRecord/267497, PublicationRecord/267498, PublicationRecord/267499, PublicationRecord/267500, PublicationRecord/267501, PublicationRecord/29812, PublicationRecord/306957, PublicationRecord/32137, PublicationRecord/33089, PublicationRecord/33399, PublicationRecord/33400, PublicationRecord/367878, PublicationRecord/385938, PublicationRecord/5192, PublicationRecord/5296, PublicationRecord/58, PublicationRecord/7636, PublicationRecord/7638, QUARTET_Eligibility_Criteria, Randomized_into_groups_for_PARACHUTE_Trial, Rate_of_Adverse_Events_of_Special_Interest_NCT03640312, Rate_of_Death_or_Major_Traumatic_Injury_on_Impact_with_comparator, Rate_of_Death_or_Major_Traumatic_Injury_on_Impact_with_intervention, Reasons_for_exclusion_from_QUARTET_USA_Trial, Remdesivir, Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days, ResearchStudy/568025, ResearchStudy/586129, ResearchStudy/588219, ResearchStudy/588222, ResearchStudyClassifierCodeSystem, Risk_of_bias_type, SEQN, SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review, SearchStrategy_PubMed_search_for_Wonder_Woman, Serious_hyperglycaemia313882, Serious_hyperglycaemia313963, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_from_MAGICapp_313882, Serious_hyperglycaemia_from_MAGICapp_313963, Severe_gastrointestinal_events313883, Severe_gastrointestinal_events313965, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_from_MAGICapp_313883, Severe_gastrointestinal_events_from_MAGICapp_313965, Severely_Obese_Adults_2018_Norwegian_Cohort, Sex, Sex_with_comparator, Sex_with_intervention, Sodium_Glucose_Transport_Protein_2_SGLT2_inhibitors85394_I_85798, Spanish_or_English_Value_Set, Standard_care85390_C_85789, StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, StudyEligibilityCriteria_Obese_patients_18_years_old, StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group, StudyGroup_DIBASY_Trial_Enrollment_Group, SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer, Systolic_blood_pressure_at_12_weeks, Therapeutic_dose_anticoagulation_with_heparin_vs_Usual_care_pharmacologic_thromboprophylaxis, Time_to_integration_of_results_in_a_recommendation, Treatment_induced_changes_in_phospho_protein_signaling_NCT05327010, Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, Velocity, Velocity_comparing_intervention_vs_comparator, Velocity_for_enrolled_group, Velocity_for_non_participant_group, Velocity_with_comparator, Velocity_with_intervention, WTSAF2YR, Weight, Weight_with_comparator, Weight_with_intervention and Year_2018_Norwegian_Cohort_Study * GTSAbbreviation: ActivityDefinition/375159, ActivityDefinition/375181 and IV_remdesivir_200_mg_then_100_mg_day_for_9_days * EvidenceVariableRole: Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY ( src )
• Treatment-induced changes in phospho-protein signaling (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583776. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583776. Computable resource at: https://fevir.net/resources/EvidenceVariable/583776#json. ( src )
• author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter: ( src )
• author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter: , Joanne Dehnbostel: ( src )
• author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: ( src )
• author: Computable Publishing®: MAGIC-to-FEvIR Converter: ( src )
• author: Computable Publishing®: MEDLINE-to-FEvIR Converter: ( src )
• observed: supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care ( src )
• suggested alternative name: GlucaGen® ( src )
• title: SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. ( src )
• © 2020 by the American Diabetes Association. ( src )
• © 2021-2025 Computable Publishing LLC, Patent Pending. ( src )
• © 2024+ HL7 International / Clinical Decision Support. ( src )
• © 2024. The Author(s). ( src )
• © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. ( src )
• © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ( src )
• © The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. ( src )

External References

Type	Reference	Content
web	fevir.net	url : https://fevir.net/resources/Composition/370505
web	fevir.net	url : https://fevir.net/resources/Composition/399874
web	fevir.net	url : https://fevir.net/resources/Composition/399872
web	fevir.net	url : https://fevir.net/resources/Composition/370503
web	fevir.net	url : https://fevir.net/resources/Composition/370510
web	fevir.net	url : https://fevir.net/resources/Composition/312203
web	fevir.net	url : https://fevir.net/resources/Composition/372776
web	fevir.net	url : https://fevir.net/resources/Composition/570077
web	fevir.net	url : https://fevir.net/resources/Composition/178426
web	fevir.net	url : https://fevir.net/resources/Composition/236538
web	fevir.net	url : https://fevir.net/resources/Composition/179465
web	fevir.net	url : https://fevir.net/resources/Composition/568072
web	fevir.net	url : https://fevir.net/resources/Composition/568057
web	fevir.net	url : https://fevir.net/resources/Composition/568051
web	fevir.net	url : https://fevir.net/resources/Composition/568070
web	fevir.net	url : https://fevir.net/resources/Composition/568055
web	fevir.net	url : https://fevir.net/resources/Composition/568059
web	fevir.net	url : https://fevir.net/resources/Composition/568044
web	fevir.net	url : https://fevir.net/resources/Composition/568049
web	fevir.net	url : https://fevir.net/resources/Composition/568064
web	fevir.net	url : https://fevir.net/resources/Composition/568043
web	fevir.net	url : https://fevir.net/resources/Composition/568056
web	fevir.net	url : https://fevir.net/resources/Composition/568052
web	fevir.net	url : https://fevir.net/resources/Composition/568054
web	fevir.net	url : https://fevir.net/resources/Composition/568050
web	fevir.net	url : https://fevir.net/resources/Composition/568046
web	fevir.net	url : https://fevir.net/resources/Composition/568048
web	fevir.net	url : https://fevir.net/resources/Composition/568045
web	fevir.net	url : https://fevir.net/resources/Composition/568060
web	fevir.net	url : https://fevir.net/resources/Composition/568053
web	fevir.net	url : https://fevir.net/resources/Composition/568047
web	fevir.net	url : https://fevir.net/resources/Composition/318262
web	fevir.net	url : https://fevir.net/resources/Composition/399873
web	fevir.net	url : https://fevir.net/resources/Composition/370504
web	fevir.net	url : https://fevir.net/resources/Composition/343007
web	fevir.net	url : https://fevir.net/resources/Composition/307245
web	fevir.net	url : https://fevir.net/resources/Composition/307248
web	fevir.net	url : https://fevir.net/resources/Composition/312172
web	fevir.net	url : https://fevir.net/resources/Composition/292951
web	fevir.net	url : https://fevir.net/resources/Composition/399871
web	fevir.net	url : https://fevir.net/resources/Composition/370502
web	fevir.net	url : https://fevir.net/resources/Composition/370512
web	fevir.net	url : https://fevir.net/resources/Composition/179699
web	fevir.net	url : https://fevir.net/resources/Composition/179466
web	fevir.net	url : https://fevir.net/resources/Composition/179467
web	fevir.net	url : https://fevir.net/resources/Composition/267224
web	fevir.net	url : https://fevir.net/resources/Composition/367880
web	fevir.net	url : https://fevir.net/resources/Composition/236537
web	fevir.net	url : https://fevir.net/resources/Composition/236951
web	fevir.net	https://fevir.net/resources/PublicationRecord/32147
web	jamanetwork.com	https://jamanetwork.com/journals/jama/fullarticle/1103994
web	jamanetwork.com	https://jamanetwork.com/journals/jama/fullarticle/2669729
web	diabetesjournals.org	https://diabetesjournals.org/care/article/39/6/861/29305/Metabolic-Surgery-in-the-Treatment-Algorithm-for
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/267500
web	doi.org	url : https://doi.org/10.1186/s40360-015-0026-9
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179629
web	doi.org	url : https://doi.org/10.1007/s00280-013-2163-4
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179637
web	doi.org	url : https://doi.org/10.1016/j.drugalcdep.2008.04.002
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179597
web	doi.org	url : https://doi.org/10.1080/10894160.2018.1450001
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179625
web	doi.org	url : https://doi.org/10.1016/j.eururo.2012.03.053
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179615
web	doi.org	url : https://doi.org/10.1016/S1470-2045(12)70560-0
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179621
web	doi.org	url : https://doi.org/10.1016/S1470-2045(15)00011-X
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179605
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/7636
web	www.nejm.org	target : https://www.nejm.org/doi/full/10.1056/NEJMe2111151
web	doi.org	url : https://doi.org/10.1056/NEJMoa2105911
web	www.nejm.org	url : https://www.nejm.org/doi/full/10.1056/NEJMoa2105911
web	www.nejm.org	url : https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105911?articleTools=true
web	www.nejm.org	url : https://www.nejm.org/doi/suppl/10.1056/NEJMoa2105911/suppl_file/nejmoa2105911_appendix.pdf
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/5192
web	doi.org	url : https://doi.org/10.1101/2021.05.13.21256846
web	www.medrxiv.org	url : https://www.medrxiv.org/content/10.1101/2021.05.13.21256846v1.full-text
web	www.medrxiv.org	url : https://www.medrxiv.org/content/10.1101/2021.05.13.21256846v1.supplementary-material
web	www.medrxiv.org	url : https://www.medrxiv.org/content/medrxiv/early/2021/05/17/2021.05.13.21256846/DC1/embed/media-1.pdf?download=true
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/105
web	doi.org	url : https://doi.org/10.1016/j.jiph.2020.09.008
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/33399
web	doi.org	url : https://doi.org/10.1093/eurheartj/ehac071
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/264329
web	doi.org	url : https://doi.org/10.1136/bmj-2022-074068
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/121719
web	doi.org	url : https://doi.org/10.17226/10027
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/139860
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/139859
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179604
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179628
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179616
web	doi.org	url : https://doi.org/10.1056/NEJMoa1503747
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/247416
web	fevir.net	url : https://fevir.net/FLI/DocumentForComposition178426
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/385938
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/7638
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/58
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179626
web	doi.org	url : https://doi.org/10.1016/S0140-6736(11)61095-7
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/29812
web	fevir.net	url : https://fevir.net/
web	fevir.net	url : https://fevir.net/resources/Project/29394
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179558
web	fevir.net	https://fevir.net/resources/Composition/178426
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179559
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/267496
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/153881
web	doi.org	url : https://doi.org/10.1016/S0140-6736(22)00538-4
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/367878
web	doi.org	url : https://doi.org/10.1038/s41440-024-01658-y
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179613
web	doi.org	url : https://doi.org/10.1371/journal.pone.0157660
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/112
web	www.medrxiv.org	url : https://www.medrxiv.org/content/10.1101/2020.08.13.20174201v1
web	www.medrxiv.org	url : https://www.medrxiv.org/content/10.1101/2020.08.13.20174201v1.full.pdf
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/267498
web	doi.org	url : https://doi.org/10.1089/dia.2015.0451
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179627
web	doi.org	url : https://doi.org/10.1016/S0140-6736(08)61815-2
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179630
web	doi.org	url : https://doi.org/10.1016/j.urolonc.2015.05.012
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179595
web	doi.org	url : https://doi.org/10.1126/science.362.6417.966
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/267497
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/267501
web	doi.org	url : https://doi.org/10.2337/dc12-2480
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179599
web	doi.org	url : https://doi.org/10.1123/jsep.2017-0028
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/267499
web	doi.org	url : https://doi.org/10.2337/dc15-1498
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179596
web	doi.org	url : https://doi.org/10.1080/10894160.2018.1449500
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/32137
web	doi.org	url : https://doi.org/10.2337/dc21-S008
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/104116
web	doi.org	url : https://doi.org/10.1001/jama.2017.21055
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179623
web	doi.org	url : https://doi.org/10.1016/j.urology.2012.12.025
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179624
web	doi.org	url : https://doi.org/10.1186/1756-8722-7-20
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/33089
web	doi.org	url : https://doi.org/10.2337/dc16-0236
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/306957
web	doi.org	url : https://doi.org/10.1136/bmj.k5094
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179631
web	doi.org	url : https://doi.org/10.1200/JCO.2007.15.9830
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/5296
web	doi.org	url : https://doi.org/10.31219/osf.io/urb6f
web	osf.io	url : https://osf.io/urb6f/
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/267246
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179622
web	doi.org	url : https://doi.org/10.1093/annonc/mdv245
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/111
web	ars.els-cdn.com	url : https://ars.els-cdn.com/content/image/1-s2.0-S1876034120306638-mmc1.pdf
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179560
web	fevir.net	url : https://fevir.net/ctgovconvert
web	fevir.net	url : https://fevir.net/resources/Project/29885
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/267247
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/33400
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179617
web	doi.org	url : https://doi.org/10.1016/j.eururo.2014.09.032
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179598
web	doi.org	url : https://doi.org/10.1152/advan.00161.2017
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179601
web	doi.org	url : https://doi.org/10.7326/W17-0068
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179600
web	doi.org	url : https://doi.org/10.7326/W17-0069
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179561
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179594
web	doi.org	url : https://doi.org/10.1016/j.jacr.2021.10.014
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179602
web	fevir.net	url : https://fevir.net/resources/PublicationRecord/179603
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/267223
web	fevir.net	target : https://fevir.net/ctgovconvert
web	www.clinicalstudydatarequest.com	target : https://www.clinicalstudydatarequest.com
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/588219
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/588222
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/346485
web	euclinicaltrials.eu	target : https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-516402-32-00
web	fevir.net	target : https://fevir.net/ctisconvert
web	tel:+33156016317	+33156016317
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/367879
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/586129
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/568025
web	fevir.net	url : https://fevir.net/resources/ResearchStudy/583768
web	github.com	Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
web	profiles.ihe.net	XDS metadata equivalent
web	profiles.ihe.net	XDS metadata equivalent
web	creativecommons.org	https://creativecommons.org/licenses/by-nc-sa/4.0/ Show Usage Evidence Based Medicine on FHIR Implementation Guide Code System : ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version , ADA_Obesity_Management_Recommendation_8_16 ... Show 390 more , Add_on_Amlodipine_at_6_weeks, AdverseEventsReport, Adverse_event_free_and_hypertension_control_at_12_weeks, Age, AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313876, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313956, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313876, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313956, All_cause_mortality_from_MAGICapp_313876, All_cause_mortality_from_MAGICapp_313956, Altitude, Analysis_of_formalin_fixed_paraffin_embedded_and_blood_and_blood_samples_NCT05327010, ArtifactAssessment/104064, ArtifactAssessment/104192, ArtifactAssessment/104193, ArtifactAssessment/104194, ArtifactAssessment/104195, ArtifactAssessment/104196, ArtifactAssessment/179448, ArtifactAssessment/179469, ArtifactAssessment/179515, ArtifactAssessment/179693, ArtifactAssessment/179698, ArtifactAssessment/179700, ArtifactAssessment/307449, ArtifactAssessment/385882, ArtifactAssessment/423309, ArtifactAssessment/423310, ArtifactAssessment/423312, ArtifactAssessment/423313, ArtifactAssessment/423314, ArtifactAssessment/423315, Assess_emergent_resistant_mutations_NCT05327010, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group, BaselineMeasureReport, Birthdate, Body_weight_Comparator_Evidence_from_MAGICapp_109570, Body_weight_Comparator_Evidence_from_MAGICapp_109588, Body_weight_Intervention_Evidence_from_MAGICapp_109570, Body_weight_Intervention_Evidence_from_MAGICapp_109588, Body_weight_from_MAGICapp_109570, Body_weight_from_MAGICapp_109588, BookCitation, BookPartCitation, CIBIC_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_from_MAGICapp_313877, Cardiovascular_mortality_from_MAGICapp_313957, Case_id, CertaintyOfEvidence, Change_in_Mean_Diastolic_Blood_Pressure_NCT03640312, Change_in_Mean_Systolic_Blood_Pressure_at_12_weeks_NCT03640312, Change_in_Mean_Systolic_Blood_Pressure_at_6_weeks_NCT03640312, Clinical_benefit_rate_CBR_NCT05327010, ComparativeBaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeBaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeEvidenceReport, ComparativeEvidenceReportExpanded, ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort, ComparativeEvidenceSynthesisReport, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial, ComparatorOnlyEvidence_Additional_GI_surgical_procedure_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_New_onset_depression_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Remission_of_diabetes_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Treatment_with_opioids_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, Composition/104215, Composition/104383, Composition/178426, Composition/179465, Composition/179466, Composition/179467, Composition/179699, Composition/236537, Composition/236538, Composition/236951, Composition/292951, Composition/307245, Composition/307248, Composition/312172, Composition/312203, Composition/318262, Composition/342828, Composition/343007, Composition/370502, Composition/370503, Composition/370504, Composition/370505, Composition/370510, Composition/370512, Composition/372776, Composition/375280, Composition/397488, Composition/399871, Composition/399872, Composition/399873, Composition/399874, Composition/570077, ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, ConceptualCohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years, ConceptualCohortDefinition_Cardiovascular_event, ConceptualCohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration, ConceptualCohortDefinition_Proxy_criteria_for_surgical_candidates, Correlate_baseline_mutations_with_treatment_response_NCT05327010, Correlate_changes_in_ctDNA_variant_allele_frequencies_with_response_NCT05327010, Correlate_mutation_profiles_with_tumor_sequencing_NCT05327010, Correlation_of_single_nucleotide_variant_SNV_and_copy_number_variant_CNV_profiles_with_treatment_response_NCT05327010, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, DIO_Mortality, DatabaseCitation, DatabaseEntryCitation, DatasetCitation, Diabetic_ketoacidosis_Comparator_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_Intervention_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_from_MAGICapp_313962, Diastolic_blood_pressure_at_12_weeks, DichotomousIntendedOutcome_Death_or_Major_Traumatic_Injury_within_30_days, Duration_of_response_NCT05327010, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_from_MAGICapp_313880, End_stage_kidney_disease_from_MAGICapp_313960, Ethnic_Group, EvidenceAssessment, EvidenceReport, EvidenceReportPackage, EvidenceReportSectionCode_Value_Set, EvidenceVariableHandlingExtensionValueSet, Example_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, Example_Variable_Definition_for_EBMonFHIR_IG, Example_variable_definition_for_the_EBMonFHIR_IG, ExposureVariable_Age_as_continuous_variable, ExposureVariable_Body_Mass_Index_as_continuous_variable, Family_History_of_Parachute_Use, Frequent_Flier, GLU_J, Gene_expression_profiling_NCT05327010, Genital_infection_Comparator_Evidence_from_MAGICapp_313964, Genital_infection_Intervention_Evidence_from_MAGICapp_313964, Genital_infection_from_MAGICapp_313964, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85390_I_85789, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85394_C_85798, Group/236535, Group/236948, Group/236949, Group/292955, Group/297486, Group/297487, Group/297488, Group/297489, Group/306655, Group/306657, Group/306658, Group/306659, Group/306660, Group/33395, Group/372797, Group/375175, Group/375182, Group/557017, Group/557018, Group/557341, Group/557342, Group/588218, GroupAssignment, GroupAssignment_Bariatric_Surgery_vs_no_bariatric_surgery, GroupAssignment_ExposureDefinition_Bariatric_Surgery_RYGB_VSG_LAGB_BPD_vs_ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, GroupAssignment_ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort_vs_ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, GroupAssignment_GLP_1_RA_vs_Standard_care, GroupAssignment_Jumping_from_aircraft_with_parachute_vs_Jumping_from_aircraft_with_empty_backpack, GroupAssignment_Non_Participants_vs_Enrolled_Participants, GroupAssignment_Quadpill_vs_Candesartan, GroupAssignment_Roux_en_Y_gastric_bypass_or_Biliopancreatic_Diversion_vs_medical_treatment, GroupAssignment_Roux_en_Y_gastric_bypass_surgery_vs_Lifestyle_intensive_medical_management_intervention_alone, GroupAssignment_Roux_en_Y_gastric_bypass_vs_medical_treatment, GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA, GroupAssignment_high_dose_xanomeline_vs_low_dose_xanomeline_vs_placebo, Guideline, Health_Survey_Score_Mental_Health_Subscore, Health_Survey_Score_Physical_Health_Subscore, Health_Survey_Score_Total, Health_related_Quality_of_Life_NCT03640312, Health_related_Quality_of_Life_at_12_weeks_Change_in_Mental_Health_T_score_PROMIS_at_NCT03640312, Health_related_Quality_of_Life_at_12_weeks_Change_in_Physical_Health_T_score_PROMIS_at_NCT03640312, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_from_MAGICapp_109569, Health_related_quality_of_life_from_MAGICapp_109587, Heart_failure_Comparator_Evidence_from_MAGICapp_313881, Heart_failure_Comparator_Evidence_from_MAGICapp_313961, Heart_failure_Intervention_Evidence_from_MAGICapp_313881, Heart_failure_Intervention_Evidence_from_MAGICapp_313961, Heart_failure_from_MAGICapp_313881, Heart_failure_from_MAGICapp_313961, History_of_Acrophobia, History_of_Broken_Bones, History_of_Parachute_Use, Hypertension_Control_at_12_weeks, Incidence_of_adverse_events_NCT05327010, International_vs_Domestic_Flight, InterventionOnlyEvidence_Additional_GI_surgical_procedure_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_New_onset_depression_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Remission_of_diabetes_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Treatment_with_opioids_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, Investigator_by_treatment_interaction_for_ADAS_Cog11_ANCOVA, JournalArticleCitation, LBDGLUSI, LBXGLU, Library/179606, Library/179618, Library/179632, MeanDiffA1c2016metaAnalysis, Mean_Change_in_Blood_Urea_Nitrogen_NCT03640312, Mean_Change_in_Serum_Creatinine_NCT03640312, Mean_Change_in_Serum_Potassium_NCT03640312, Mean_Change_in_Serum_Sodium_NCT03640312, Mean_Diastolic_Blood_Pressure_NCT03640312, Mean_Systolic_Blood_Pressure_NCT03640312, Median_Age_SD, Medication_Adherence_NCT03640312, Medication_Adherence_at_12_weeks, MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, NCT03421379_Results, NCT03640312_Results, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_from_MAGICapp_313878, Nonfatal_myocardial_infarction_from_MAGICapp_313958, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313959, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313959, Nonfatal_stroke_from_MAGICapp_313879, Nonfatal_stroke_from_MAGICapp_313959, Ntprobnp_comparator, Ntprobnp_date, Ntprobnp_time, Number_of_Patients_Requiring_Step_up_Treatment_NCT03640312, Objective_response_rate_ORR_NCT05327010, OutcomeDefinition_Diabetes_in_remission, OutcomeDefinition_HbA1c_at_12_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_6_months, OutcomeDefinition_New_onset_depression, OutcomeImportance, OutcomeMeasureReport, OutcomeVariable_Additional_GI_surgical_procedure, OutcomeVariable_HbA1c_at_12_months, OutcomeVariable_HbA1c_at_24_months, OutcomeVariable_HbA1c_at_36_months, OutcomeVariable_HbA1c_at_60_months, OutcomeVariable_HbA1c_at_6_months, OutcomeVariable_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, OutcomeVariable_New_onset_depression, OutcomeVariable_Remission_of_diabetes, OutcomeVariable_Treatment_with_opioids, Outcome_Death_or_Major_Traumatic_Injury_30_days_after_Impact, Outcome_Death_or_Major_Traumatic_Injury_on_Impact, Outcome_Injury_Severity_Score_30_days_after_Impact, Outcome_Injury_Severity_Score_on_Impact, Overall_survival_NCT05327010, PARACHUTE_Trial_Participants_available_for_randomization, PARACHUTE_Trial_Participants_deemed_unsuitable_by_investigator, PARACHUTE_Trial_Participants_randomized_into_groups, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up, PARACHUTE_Trial_Participants_that_declined_randomization, PARACHUTE_Trial_Participants_with_no_contact_at_30_days, PD_Time_to_Maximal_Concentration_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, PICOClassification, PICOSpecification, PICOTaggedComposition, PICOTaggedEvidence, PK_Change_From_Baseline_in_Maximal_Concentration_Cmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, PK_Change_From_Baseline_in_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, Parachute_vs_Empty_Backpack_in_PARACHUTE_Trial, ParticipantFlowEvidence_2018_Norwegian_Cohort_Excluded_from_Analysis, ParticipantFlowMeasure_Dropout_due_to_stopping_intervention, ParticipantFlowMeasure_Exclusion_from_analysis, ParticipantFlowMeasure_Inclusion_in_analysis, ParticipantFlowReport, ParticipantFlow_2018_Norwegian_Cohort_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Medical_Group_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Surgical_Group_Included_in_Analysis, Participants_Excluded_from_PARACHUTE_Study, Patient_id, Percentage_of_Participants_Achieving_Treatment_Success_During_Controlled_Insulin_Induced_Hypoglycemia_NCT03421379, Percentage_of_Participants_With_Clinical_Recovery_Within_14_Days_After_Randomization_NCT04401202, Percentage_of_Participants_With_Potentially_Related_Adverse_Events_NCT03640312, Percentage_of_Participants_With_Serious_Adverse_Events_SAEs_NCT03640312, Pharmacodynamics_PD_Change_From_Baseline_in_Maximal_Blood_Glucose_BGmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_Intramuscular_IM_NCT03421379, Pharmacokinetics_PK_Change_From_Baseline_in_Area_Under_the_Concentration_Versus_Time_Curve_From_Zero_to_Time_t_AUC_0_tLast_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379, PlanDefinition/179554, PreprintCitation, Progression_free_survival_NCT05327010, Proportion_of_Patients_With_Adverse_Event_Free_Hypertension_Control_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_at_6_and_12_weeks_12_weeks_at_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_at_6_and_12_weeks_6_weeks_at_NCT03640312, PublicationRecord/121719, PublicationRecord/139859, PublicationRecord/139860, PublicationRecord/179558, PublicationRecord/179559, PublicationRecord/179560, PublicationRecord/247416, PublicationRecord/385938, PublicationRecord/58, PublicationRecord/7636, Rate_of_Adverse_Events_of_Special_Interest_NCT03640312, Reasons_for_exclusion_from_QUARTET_USA_Trial, Recommendation, RecommendationJustification, RecommendationRating, ResearchStudyDataDictionary, RiskOfBias, SEQN, SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review, SearchStrategy_PubMed_search_for_Wonder_Woman, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_from_MAGICapp_313882, Serious_hyperglycaemia_from_MAGICapp_313963, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_from_MAGICapp_313883, Severe_gastrointestinal_events_from_MAGICapp_313965, Sex, Sodium_Glucose_Transport_Protein_2_SGLT2_inhibitors85394_I_85798, SoftwareCitation, Standard_care85390_C_85789, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, StudyGroup_DIBASY_Trial_Enrollment_Group, SummaryOfFindings, SummaryOfNetEffect, SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer, Systolic_blood_pressure_at_12_weeks, Therapeutic_dose_anticoagulation_with_heparin_vs_Usual_care_pharmacologic_thromboprophylaxis, Time_to_integration_of_results_in_a_recommendation, Treatment_induced_changes_in_phospho_protein_signaling_NCT05327010, Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, Velocity, WTSAF2YR, WebPageCitation and Weight ResearchStudy Classifier Code System : CTIS_2024_516402_32_00_FHIR_Transform , NCT03421379_FHIR_Transform ... Show 6 more , NCT03640312_FHIR_Transform, NCT05327010_FHIR_Transform, ResearchStudyClassifier, ResearchStudySite, StudyDesign and StudyRegistryRecord
web	creativecommons.org	https://creativecommons.org/licenses/by-sa/4.0/ Show Usage Recommendation Justification Code System : All_cause_mortality_from_MAGICapp_313876 , All_cause_mortality_from_MAGICapp_313956 ... Show 25 more , ArtifactAssessment/179515, ArtifactAssessment/385882, Body_weight_from_MAGICapp_109570, Body_weight_from_MAGICapp_109588, Cardiovascular_mortality_from_MAGICapp_313877, Cardiovascular_mortality_from_MAGICapp_313957, Diabetic_ketoacidosis_from_MAGICapp_313962, End_stage_kidney_disease_from_MAGICapp_313880, End_stage_kidney_disease_from_MAGICapp_313960, Genital_infection_from_MAGICapp_313964, Health_related_quality_of_life_from_MAGICapp_109569, Health_related_quality_of_life_from_MAGICapp_109587, Heart_failure_from_MAGICapp_313881, Heart_failure_from_MAGICapp_313961, Nonfatal_myocardial_infarction_from_MAGICapp_313878, Nonfatal_myocardial_infarction_from_MAGICapp_313958, Nonfatal_stroke_from_MAGICapp_313879, Nonfatal_stroke_from_MAGICapp_313959, RecommendationJustification, RecommendationJustificationClassifier, RecommendationRating, Serious_hyperglycaemia_from_MAGICapp_313882, Serious_hyperglycaemia_from_MAGICapp_313963, Severe_gastrointestinal_events_from_MAGICapp_313883 and Severe_gastrointestinal_events_from_MAGICapp_313965
web	fevir.net	Scientific Evidence Code System (SEVCO)
web	fevir.net	Recommendation Justification Code System
web	fevir.net	Evidence Based Medicine on FHIR Implementation Guide Code System
web	fevir.net	ResearchStudy Classifier Code System
web	fevir.net	EvidenceReportSectionCode Value Set
web	fevir.net	ResearchStudy Classifier Value Set
web	fevir.net	or use the FEvIR API .

Internal Images

tree-filter.png